Solara Pharma Issues Final Call Money Notice; Forfeiture Risk for Defaulting Shareholders
Solara Active Pharma Sciences has issued a final notice for outstanding call money on partly paid-up equity shares. Shareholders must pay the First Call (₹131.25) and Second Call (₹112.50) by July 27, 2026, to avoid forfeiture. Payment is due for both calls combined.
The announcement directly impacts a specific group of shareholders who hold partly paid-up shares and have not yet made the required payments. The potential forfeiture of shares could have a material impact on these individuals.
The announcement concerns a final notice for payment of call money, with a risk of forfeiture of shares for non-compliance, which is a negative development for affected shareholders.
Solara Active Pharma Sciences Limited has issued a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up equity shares who have not yet paid their First Call or Second and Final Call money.
The notice informs shareholders that failure to pay the outstanding call money by the specified deadline will result in the forfeiture of their partly paid-up equity shares, including any amount already paid.
The payment period for the First Call (₹131.25 per share) and the Second and Final Call (₹112.50 per share) is from Monday, July 13, 2026, to Monday, July 27, 2026. Shareholders are required to pay the full outstanding amount for both calls through the online portal at https://rights.cameoindia.com/solaracallmoney2.
Payments must be made in full, and no part payments will be accepted. The company has also noted that the ISINs for the partly paid-up equity shares have been suspended from trading. The process of converting these shares to fully paid-up equity shares is estimated to be completed within two to three weeks after the payment period, subject to the Board's decision.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.